BYSI - BeyondSpring Inc.

1.51
-0.050   -3.311%

Share volume: 4,583
Last Updated: 04-28-2026
Pharmaceutical Products/Pharmaceutical Preparations: -0.12%

PREVIOUS CLOSE
CHG
CHG%
$1.56
-0.05
-0.03%
5D - 1M - 3M - 1Y - 3Y - 5Y - 10Y - 15Y
Overview Charts Financials Fundamental analysis Historical prices Events Documents Notes Dividends
Fundamental analysis
23%
Profitability 25%
Dept financing 12%
Liquidity 58%
Performance 15%
Company vs Stock growth
vs
+ Add row to compare
Performance
5 Days
-11.44%
1 Month
-6.79%
3 Months
-3.21%
6 Months
-17.49%
1 Year
-2.58%
2 Year
-31.98%
Key data
Stock price
$1.51
P/E Ratio 
N/A
DAY RANGE
$1.43 - $1.58
EPS 
-$0.02
52 WEEK RANGE
$1.21 - $3.44
52 WEEK CHANGE
-$13.22
MARKET CAP 
0.000
YIELD 
N/A
SHARES OUTSTANDING 
41.120 M
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
N/A
BETA 
1.44
PUBLIC FLOAT 
$0
AVERAGE 10 VOLUME 
$10,008
AVERAGE 30 VOLUME 
$10,203
Company detail
CEO: Lan Huang
Region: US
Website: beyondspringpharma.com
Employees: 80
IPO year: 2017
Issue type: Common Stock
Market: XNAS
Industry: Pharmaceutical Products/Pharmaceutical Preparations
Sector: Manufacturing

Plinabulin, a selective immune-modulating microtubule-binding agent, has completed Phase III clinical trials for the prevention of chemotherapy-induced neutropenia; and for treatment of later-stage non-small cell lung cancer. BeyondSpring Inc. is a clinical stage biopharmaceutical company. Company engages in the development of three small molecule immune agents in preclinical stages; and drug development platform.

Recent news